A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency
A Phase III, Randomized, Open-label, Positive-controlled, Multi-center Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency
Sponsor: TJ Biopharma Co., Ltd.
A PHASE3 clinical study on Pediatric Growth Hormone Deficiency, this trial is completed. The trial is conducted by TJ Biopharma Co., Ltd. and has accumulated 12 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Dec 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2023 — May 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
▶ Show 7 earlier versions
-
May 2023 — Oct 2023 [monthly]
Recruiting PHASE3
-
Sep 2022 — May 2023 [monthly]
Recruiting PHASE3
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE3
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Mar 2021 — May 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- TJ Biopharma Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Guangzhou, China , Hefei, China , Hengyang, China , Jining, China , Linyi, China , Liuchow, China and 14 more locations